Search research articles
Contact Us
Filters
Showing results (61-70 of 96) with videos related to
Page
of 10
Sort By:
Plos One
|
April 9, 2020
FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis
Sven F Garbade, Matthias Zielonka, Konstantin Mechler, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|
May 25, 2006
Disease manifestations and X inactivation in heterozygous females with Fabry disease
Esther M Maier, Stephanie Osterrieder, Catharina Whybra, et al.
Plos One
|
August 15, 2015
Clinical Research in Vulnerable Populations: Variability and Focus of Institutional Review Boards' Responses
Bärbel Kästner, Simone Behre, Nadine Lutz, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine
|
September 12, 2024
Laryngeal mask vs. laryngeal tube trial in paediatric patients (LaMaTuPe): a single-blinded, open-label, randomised-controlled trial
Stephan Katzenschlager, Stefan Mohr, Nikolai Kaltschmidt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 4, 2022
Quantitative longitudinal natural history of 8 gangliosidoses-conceptual framework and baseline data of the German 8-in-1 disease registry. A cross-sectional analysis
Markus Ries, Grecia Mendoza, Laila Arash-Kaps, et al.
Kidney International
|
August 26, 2004
Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease
Markus Ries, Karen E Bove Bettis, Peter Choyke, et al.
Journal of Clinical Pharmacology
|
August 19, 2007
Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents
Markus Ries, Joe T Clarke, Catharina Whybra, et al.
Pharmaceutics
|
February 26, 2022
Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting
Markus Ries, Brice Moulari, Maryam A Shetab Boushehri, et al.
Therapeutic Advances in Respiratory Disease
|
January 7, 2026
Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA
Philipp Höger, Markus Ries, Arturo Olivares Rivera, et al.
Studies in Health Technology and Informatics
|
August 8, 2013
Workflows in cancer treatment and their influence upon clinical documentation
Thomas Bürkle, Marcus Martin, Alexander Schütz, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 96) with videos related to
Sort By:
Page
of 10
Plos One
|
April 9, 2020
FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis
Sven F Garbade, Matthias Zielonka, Konstantin Mechler, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|
May 25, 2006
Disease manifestations and X inactivation in heterozygous females with Fabry disease
Esther M Maier, Stephanie Osterrieder, Catharina Whybra, et al.
Plos One
|
August 15, 2015
Clinical Research in Vulnerable Populations: Variability and Focus of Institutional Review Boards' Responses
Bärbel Kästner, Simone Behre, Nadine Lutz, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine
|
September 12, 2024
Laryngeal mask vs. laryngeal tube trial in paediatric patients (LaMaTuPe): a single-blinded, open-label, randomised-controlled trial
Stephan Katzenschlager, Stefan Mohr, Nikolai Kaltschmidt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 4, 2022
Quantitative longitudinal natural history of 8 gangliosidoses-conceptual framework and baseline data of the German 8-in-1 disease registry. A cross-sectional analysis
Markus Ries, Grecia Mendoza, Laila Arash-Kaps, et al.
Kidney International
|
August 26, 2004
Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease
Markus Ries, Karen E Bove Bettis, Peter Choyke, et al.
Journal of Clinical Pharmacology
|
August 19, 2007
Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents
Markus Ries, Joe T Clarke, Catharina Whybra, et al.
Pharmaceutics
|
February 26, 2022
Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting
Markus Ries, Brice Moulari, Maryam A Shetab Boushehri, et al.
Therapeutic Advances in Respiratory Disease
|
January 7, 2026
Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA
Philipp Höger, Markus Ries, Arturo Olivares Rivera, et al.
Studies in Health Technology and Informatics
|
August 8, 2013
Workflows in cancer treatment and their influence upon clinical documentation
Thomas Bürkle, Marcus Martin, Alexander Schütz, et al.
Page
of 10